Table of Contents Author Guidelines Submit a Manuscript
Advances in Bioinformatics
Volume 2014 (2014), Article ID 104823, 10 pages
http://dx.doi.org/10.1155/2014/104823
Research Article

Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens

1Bioinformatics Group, Department of Chemistry, Faculty of Mathematics and Science, University of Indonesia, Depok 16424, Indonesia
2Mathematics Computation Group, Department of Mathematics, Faculty of Mathematics and Science, University of Indonesia, Depok 16424, Indonesia

Received 3 June 2014; Revised 12 August 2014; Accepted 12 August 2014; Published 24 August 2014

Academic Editor: Antoine van Kampen

Copyright © 2014 Ridla Bakri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Cervical Cancer Summary Report, 2010.
  2. U. S. F. Tambunan and A. A. Parikesit, “HPV bioinformatics: in silico detection, drug design and prevention agent development,” in Topics on Cervical Cancer With an Advocacy for Prevention, R. Rajkumar, Ed., pp. 237–252, Intech Publishing, Rijeka, Croatia, 2012, http://www.intechopen.com/articles/show/title/hpv-bioinformatics-in-silico-detection-and-prevention-agent-development. View at Google Scholar
  3. Cancer Research UK, “CancerStats—Cancer Worldwide,” 2013.
  4. H. zur Hausen, “Papillomaviruses in the causation of human cancers—a brief historical account,” Virology, vol. 384, no. 2, pp. 260–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. H. zur Hausen, “Human papillomavirus & cervical cancer,” Indian Journal of Medical Research, vol. 130, no. 3, p. 209, 2009. View at Google Scholar
  6. H. Zur Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” Nature Reviews Cancer, vol. 2, no. 5, pp. 342–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. P. T. Soliman, B. M. Slomovitz, and J. K. Wolf, “Mechanisms of cervical cancer,” Drug Discovery Today: Disease Mechanisms, vol. 1, pp. 253–258, 2004. View at Publisher · View at Google Scholar
  8. J. Paavonen, “Human papillomavirus infection and the development of cervical cancer and related genital neoplasias,” International Journal of Infectious Diseases, vol. 11, supplement 2, pp. S3–S9, 2007. View at Publisher · View at Google Scholar
  9. H. Trottier and A. N. Burchell, “Epidemiology of mucosal human papillomavirus infection and associated diseases,” Public Health Genomics, vol. 12, no. 5-6, pp. 291–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. R. Pagliusi, J. Dillner, M. Pawlita, W. G. V. Quint, C. M. Wheeler, and M. Ferguson, “Chapter 23: international Standard reagents for harmonization of HPV serology and DNA assays-an update,” Vaccine, vol. 24, no. 3, pp. S193–S200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Steben and E. Duarte-Franco, “Human papillomavirus infection: epidemiology and pathophysiology,” Gynecologic Oncology, vol. 107, no. 2, pp. S2–S5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Boccardo, A. P. Lepique, and L. L. Villa, “The role of inflammation in HPV carcinogenesis,” Carcinogenesis, vol. 31, no. 11, pp. 1905–1912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Zur Hausen, “Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 690–698, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Gewin, H. Myers, T. Kiyono, and D. A. Galloway, “Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex,” Genes and Development, vol. 18, no. 18, pp. 2269–2282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. W. Łuczak and P. P. Jagodzinski, “Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells,” Cancer Letters, vol. 272, no. 1, pp. 53–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Münger, A. Baldwin, K. M. Edwards et al., “Mechanisms of human papillomavirus-induced oncogenesis,” Journal of Virology, vol. 78, no. 21, pp. 11451–11460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Herbein and D. Wendling, “Histone deacetylases in viral infections,” Clinical Epigenetics, vol. 1, no. 1-2, pp. 13–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Szalmás and J. Kónya, “Epigenetic alterations in cervical carcinogenesis,” Seminars in Cancer Biology, vol. 19, no. 3, pp. 144–152, 2009. View at Publisher · View at Google Scholar
  19. P. Finzer, A. Aguilar-Lemarroy, and F. Rösl, “The role of human papillomavirus oncoproteins E6 and E7 in apoptosis,” Cancer Letters, vol. 188, no. 1-2, pp. 15–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Park, E. J. Kim, H. J. Kwon, E. S. Hwang, S. E. Namkoong, and S. J. Um, “Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis,” The Journal of Biological Chemistry, vol. 275, no. 10, pp. 6764–6769, 2000. View at Publisher · View at Google Scholar
  21. G. Bouchain and D. Delorme, “Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation,” Current Medicinal Chemistry, vol. 10, no. 22, pp. 2359–2372, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. G. P. Delcuve, D. H. Khan, and J. R. Davie, “Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors,” Clinical Epigenetics, vol. 4, no. 1, article 5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Kuo and C. D. Allis, “Roles of histone acetyltransferases and deacetylases in gene regulation,” Bioessays, vol. 20, pp. 615–626, 1998. View at Publisher · View at Google Scholar
  25. C. L. Woodcock and R. P. Ghosh, “Chromatin higher-order structure and dynamics,” Cold Spring Harbor Perspectives in Biology, vol. 2, Article ID a000596, 2010. View at Publisher · View at Google Scholar
  26. G. Legube and D. Trouche, “Regulating histone acetyltransferases and deacetylases,” EMBO Reports, vol. 4, no. 10, pp. 944–947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. B. R. Keppler and T. K. Archer, “Chromatin-modifying enzymes as therapeutic targets: part 2,” Expert Opinion on Therapeutic Targets, vol. 12, no. 11, pp. 1457–1467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Dell'Aversana, I. Lepore, and L. Altucci, “HDAC modulation and cell death in the clinic,” Experimental Cell Research, vol. 318, pp. 1229–1244, 2012. View at Publisher · View at Google Scholar
  29. K. Darvas, S. Rosenberger, D. Brenner et al., “Histone deacetylase inhibitor-induced sensitization to TNFα/TRAIL- mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression,” International Journal of Cancer, vol. 127, no. 6, pp. 1384–1392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. S. Finnin, J. R. Donigian, A. Cohen et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,” Nature, vol. 401, no. 6749, pp. 188–193, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Chen, L. Xu, and O. Wiest, “Computational exploration of zinc binding groups for HDAC inhibition,” Journal of Organic Chemistry, vol. 78, pp. 5051–5055, 2013. View at Publisher · View at Google Scholar
  32. S.-K. Anandan, J. S. Ward, R. D. Brokx, M. R. Bray, D. V. Patel, and X. Xiao, “Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 8, pp. 1969–1972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Thangapandian, S. John, Y. Lee, V. Arulalapperumal, and K. W. Lee, “Molecular modeling study on tunnel behavior in different histone deacetylase isoforms,” PLoS ONE, vol. 7, Article ID e49327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Bertrand, “Inside HDAC with HDAC inhibitors,” European Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 2095–2116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Marek, A. Hamacher, F. K. Hansen et al., “Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells,” Journal of Medicinal Chemistry, vol. 56, no. 2, pp. 427–436, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Rajak, P. Kumar, P. Parmar et al., “Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors,” European Journal of Medicinal Chemistry, vol. 53, pp. 390–397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. P. C. Chen, V. Patil, W. Guerrant, P. Green, and A. K. Oyelere, “Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group,” Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 4839–4853, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Huang, X. Li, Y. Wei, and Z. Xiu, “A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)- disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study,” European Journal of Medicinal Chemistry, vol. 52, pp. 111–122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Calvaresi and F. Zerbetto, “In silico carborane docking to proteins and potential drug targets,” Journal of Chemical Information and Modeling, vol. 51, no. 8, pp. 1882–1896, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Korkmaz, E. Uzgören, S. Bakirdere, F. Aydin, and O. Y. Ataman, “Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells,” Environmental Toxicology, vol. 22, no. 1, pp. 17–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. J. Baker, C. Z. Ding, T. Akama, Y.-K. Zhang, V. Hernandez, and Y. Xia, “Therapeutic potential of boron-containing compounds,” Future Medicinal Chemistry, vol. 1, pp. 1275–1288, 2009. View at Publisher · View at Google Scholar
  42. J. F. Valliant, K. J. Guenther, A. S. King et al., “The medicinal chemistry of carboranes,” Coordination Chemistry Reviews, vol. 232, pp. 173–230, 2002. View at Publisher · View at Google Scholar
  43. F. Issa, M. Kassiou, and L. M. Rendina, “Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds,” Chemical Reviews, vol. 111, no. 9, pp. 5701–5722, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. U. S. F. Tambunan, I. K. Limans, and A. A. Parikesit, “Molecular dynamic simulation of complex NS2B-NS3 DENV2 protease with potential inhibitors of cyclic tripeptide,” African Journal of Biotechnology, vol. 12, no. 28, pp. 4419–4431, 2013. View at Publisher · View at Google Scholar
  45. A. A. Parikesit, K. Kinanty, and U. S. F. Tambunan, “Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics,” Pakistan Journal of Biological Sciences, vol. 16, pp. 1836–1848, 2013. View at Publisher · View at Google Scholar
  46. U. S. F. Tambunan, A. A. Parikesit, T. Prasetia, and D. Kerami, “In silico molecular interaction studies of suberoylanilide hydroxamic acid and its modified compounds with histones deacetylase class II Homo sapiens as curative measure towards cervical cancer,” Engineering, vol. 5, pp. 203–206, 2013. View at Publisher · View at Google Scholar
  47. U. S. F. Tambunan, A. Randy, and A. A. Parikesit, “Design of Candida antarctica lipase B thermostability improvement by introducing extra disulfide bond into the enzyme,” OnLine Journal of Biological Sciences, vol. 14, no. 2, pp. 108–118, 2014. View at Publisher · View at Google Scholar
  48. U. S. F. Tambunan, N. Apriyanti, A. A. Parikesit, W. Chua, and K. Wuryani, “Computational design of disulfide cyclic peptide as potential inhibitor of complex NS2B-NS3 dengue virus protease,” African Journal of Biotechnology, vol. 10, no. 57, pp. 12281–12290, 2011. View at Google Scholar · View at Scopus
  49. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 23, no. 1–3, pp. 3–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Lagorce, O. Sperandio, H. Galons, M. A. Miteva, and B. O. Villoutreix, “FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects,” BMC Bioinformatics, vol. 9, article 396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. N. A. Petasis, “Expanding roles for organoboron compounds—versatile and valuable molecules for synthetic, biological and medicinal chemistry,” Australian Journal of Chemistry, vol. 60, no. 11, pp. 795–798, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Penner, V. Rauniyar, L. T. Kaspar, and D. G. Hall, “Catalytic asymmetric synthesis of palmerolide a via organoboron methodology,” Journal of the American Chemical Society, vol. 131, no. 40, pp. 14216–14217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. V. P. Singh, R. V. Singh, and J. P. Tandon, “Stereochemical and biochemical aspects of some organoboron complexes of sulphur donor ligands,” Journal of Inorganic Biochemistry, vol. 39, pp. 237–245, 1990. View at Publisher · View at Google Scholar
  54. R. Tiwari, K. Mahasenan, R. Pavlovicz, C. Li, and W. Tjarks, “Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide, and Surflex,” Journal of Chemical Information and Modeling, vol. 49, no. 6, pp. 1581–1589, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. C. Cunningham, “Talabostat,” Expert Opinion on Investigational Drugs, vol. 16, no. 9, pp. 1459–1465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Tafi, M. Agamennone, P. Tortorella, S. Alcaro, C. Gallina, and M. Botta, “AMBER force field implementation of the boronate function to simulate the inhibition of β-lactamases by alkyl and aryl boronic acids,” European Journal of Medicinal Chemistry, vol. 40, no. 11, pp. 1134–1142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. U. S. F. Tambunan, F. Fadilah, and A. A. Parikesit, “Bioactive compounds screening from Zingiberaceae family as influenza a/swine flu virus neuraminidase inhibitor through docking approach,” OnLine Journal of Biological Sciences, vol. 10, no. 4, pp. 151–156, 2010. View at Google Scholar · View at Scopus
  58. U. S. F. Tambunan, R. Bakri, T. Prasetia, A. A. Parikesit, and D. Kerami, “Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer,” Bioinformation, vol. 9, pp. 696–700, 2013, http://www.bioinformation.net/009/97320630009696.htm. View at Google Scholar
  59. P. Hunter, “Not boring at all. Boron is the new carbon in the quest for novel drug candidates,” EMBO Reports, vol. 10, no. 2, pp. 125–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Hall, “Structure, properties, and preparation of boronic acid derivatives. Overview of their reactions and applications,” in Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine, chapter 1, pp. 1–99, 2006. View at Publisher · View at Google Scholar
  61. Organoboron.com, “4-piperazin-1-ylphenylboronic acid,” synthesis and properties, Organoboron.com, 2003, http://www.organoborons.com/data/structure-650.html.
  62. C. Chen, P. Dagneau, E. J. J. Grabowski et al., “Practical asymmetric synthesis of a potent Cathepsin K inhibitor. Efficient palladium removal following Suzuki coupling,” Journal of Organic Chemistry, vol. 68, no. 7, pp. 2633–2638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. A. T. de Albuquerque Silva, A. Silva, M. C. Chung et al., “Advances in prodrug design,” Mini-Reviews in Medicinal Chemistry, vol. 5, no. 10, pp. 893–914, 2005. View at Publisher · View at Google Scholar
  64. Y. Endo, T. Yoshimi, K. Kimura, and A. Itai, “Protein kinase C modulators bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore,” Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 17, pp. 2561–2564, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Tiwari, A. Toppino, H. K. Agarwal et al., “Synthesis, biological evaluation, and radioiodination of halogenated closo -carboranylthymidine analogues,” Inorganic Chemistry, vol. 51, no. 1, pp. 629–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. D. S. Wilbur, D. K. Hamlin, R. R. Srivastava, and M. Chyan, “Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives,” Nuclear Medicine and Biology, vol. 31, no. 4, pp. 523–530, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. G. A. Molander, S. L. J. Trice, and S. D. Dreher, “Palladium-catalyzed, direct boronic acid synthesis from aryl chlorides: a simplified route to diverse boronate ester derivatives,” Journal of the American Chemical Society, vol. 132, no. 50, pp. 17701–17703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Ertl and A. Schuffenhauer, “Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions,” Journal of Cheminformatics, vol. 1, no. 1, article no. 8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Boda, T. Seidel, and J. Gasteiger, “Structure and reaction based evaluation of synthetic accessibility,” Journal of Computer-Aided Molecular Design, vol. 21, no. 6, pp. 311–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. J. C. Baber and M. Feher, “Predicting synthetic accessibility: application in drug discovery and development,” Mini-Reviews in Medicinal Chemistry, vol. 4, no. 6, pp. 681–692, 2004. View at Google Scholar · View at Scopus